Amgen (AMGN) Gains from Investment Securities (2009 - 2026)

Amgen (AMGN) has reported Gains from Investment Securities for 18 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 92.0% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at -$14.0 million (down 105.83% YoY), while the FY2025 annual figure was $32.0 million, down 81.92% from the prior year.
• Gains from Investment Securities came in at $4.0 million for Q1 2026 at Amgen, up from -$69.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $355.0 million in Q4 2023, with the low at -$492.0 million in Q3 2023.
• Average Gains from Investment Securities over 5 years is -$6.5 million, with a median of $4.0 million recorded in 2026.
• The largest YoY upside for Gains from Investment Securities was 1443.48% in 2023 against a maximum downside of 5366.67% in 2023.
• Year by year, Gains from Investment Securities stood at $23.0 million in 2022, then jumped by 1443.48% to $355.0 million in 2023, then declined by 27.32% to $258.0 million in 2024, then plunged by 126.74% to -$69.0 million in 2025, then soared by 105.8% to $4.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $4.0 million, -$69.0 million, and $45.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.